Immuron Ltd (IMRN) Form 6-K — Jul 27, 2026
Immuron reported fiscal year 2026 results with global sales revenue increasing 6% to A$7.7 million, driven by 10% growth in Australia and 7% growth in the U.S. The company ended the period with A$10.0 million in cash, sufficient to fund commercial operations for approximately 22.5 months based on first-half burn rates. Management announced a strategic reset focused on partnering its clinical assets IMM-124E and IMM-529 to fund future development and commercialization. IMM-529, which targets C.
Key figures
- Revenue
- A$7.7 million
- Revenue Yoy
- 6
- Cash Position
- A$10.0 million
- Shares Outstanding
- 322848081
- Us Revenue
- A$1.8 million
- Hy26 EBITDX
- -A$1.1 million
- Canada Revenue
- A$0.2 million
- Australia Revenue
- A$5.8 million
- Imm529 Peak Sales Est
- US$400 million
- Imm124e Peak Sales Est
- US$102 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.